How Covid-19 changed biotechnology
On 11 March 2020, the World Health Organisation officially declared what everybody already knew: Covid-19 had become a pandemic. The two years that have elapsed since then changed the world in ways that most of us never thought possible. Most of these changes have been for the worse, but one of the few benefits may be the way that the crisis has accelerated biotechnology research and development.
Even before Covid-19 appeared, there had been many major advances in biotechnology, with an “extraordinary” amount of recent innovation and growth, say Linden Thomson and Cinney Zhang, who run the biotech strategy at AXA Investment Management. But the pandemic has put the sector “centre stage” and the vast amounts spent will have long-term implications in fields from drug development to the way clinical trials are conducted and the greater use of artificial intelligence.
A revolution in vaccines
One of the main outcome of the crisis is the “major advances” in vaccine technology, says Max Herrmann, who heads the healthcare team at investment bank Stifel. In particular, the successful use of messenger RNA (mRNA) vaccines is a gamechanger, with big long-term implications for how vaccines are developed. In contrast to
You’re reading a preview, subscribe to read more.
Start your free 30 days